Product NDC: | 0069-0171 |
Proprietary Name: | Doxorubicin Hydrochloride |
Non Proprietary Name: | Doxorubicin Hydrochloride |
Active Ingredient(s): | 2 mg/mL & nbsp; Doxorubicin Hydrochloride |
Administration Route(s): | INTRAVENOUS |
Dosage Form(s): | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0069-0171 |
Labeler Name: | Pfizer Laboratories Div Pfizer Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA200170 |
Marketing Category: | ANDA |
Start Marketing Date: | 20111029 |
Package NDC: | 0069-0171-01 |
Package Description: | 25 mL in 1 VIAL (0069-0171-01) |
NDC Code | 0069-0171-01 |
Proprietary Name | Doxorubicin Hydrochloride |
Package Description | 25 mL in 1 VIAL (0069-0171-01) |
Product NDC | 0069-0171 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Doxorubicin Hydrochloride |
Dosage Form Name | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
Route Name | INTRAVENOUS |
Start Marketing Date | 20111029 |
Marketing Category Name | ANDA |
Labeler Name | Pfizer Laboratories Div Pfizer Inc. |
Substance Name | DOXORUBICIN HYDROCHLORIDE |
Strength Number | 2 |
Strength Unit | mg/mL |
Pharmaceutical Classes | Anthracycline Topoisomerase Inhibitor [EPC],Anthracyclines [Chemical/Ingredient],Topoisomerase Inhibitors [MoA] |